Published on 28/12/2025
Improving Access to Rare Disease Trials Through Travel Support and Remote Visits
Addressing the Burden of Travel in Rare Disease Clinical Trials
In rare disease clinical trials, eligible patients are often scattered across large geographic regions, frequently far from study sites. The need to travel long distances—sometimes across states or international borders—can deter participation, particularly for families already managing the emotional and financial stress of a rare diagnosis.
To reduce this barrier, travel reimbursement programs and remote visit options have become essential tools for patient-centric trial design. They increase participation, reduce dropout rates, and align with global regulatory expectations for equitable trial access. According to a 2023 industry report, trials offering travel support achieved 35% faster enrollment compared to those without such provisions.
Common Travel-Related Challenges Faced by Rare Disease Patients
Rare disease participants face unique logistical and financial hurdles when joining a clinical trial. These include:
- Long-distance travel due to limited site availability
- Need for caregiver accompaniment and child care for siblings
- Mobility impairments requiring special transport accommodations
- Frequent follow-up visits over extended trial durations
- Visa and cross-border travel arrangements for global studies
Failure to address these issues can lead to site under-enrollment, protocol deviations, or skewed data from non-diverse populations.
Designing a Travel Reimbursement Program: Key Components
A structured, transparent travel reimbursement framework is critical for trial success. It must be compliant with ethical guidelines, easy for patients to navigate, and consistently applied. Key elements include:
- Eligibility Criteria: Define who qualifies (e.g., patient + 1 caregiver)
- Covered Expenses: Air/train fare, lodging, meals, local transportation
- Pre-Approval Process: Prevent misuse and clarify expectations
- Advance Payment Options: Minimize out-of-pocket burden
- Third-Party Logistics Partners: Manage bookings and reimbursements
Sample Reimbursement Table:
| Expense Category | Maximum Allowance (USD) | Notes |
|---|---|---|
| Airfare (Economy) | $800/round trip | With 14-day advance notice |
| Hotel Accommodation | $150/night | Up to 2 nights per visit |
| Meals | $50/day | Patient and 1 caregiver |
Documentation such as receipts, boarding passes, and signed logs are typically required for audit compliance.
Implementing Remote Visit Solutions
Remote visits are a complementary solution that can eliminate the need for travel altogether. These virtual touchpoints, conducted via secure telehealth platforms, allow study teams to conduct assessments, monitor safety, and collect patient-reported data from home.
Common remote visit use cases in rare disease trials include:
- Electronic informed consent (eConsent) discussions
- Follow-up safety check-ins and adverse event monitoring
- Remote completion of ePRO (electronic patient-reported outcomes)
- Behavioral assessments via video in neurodevelopmental disorders
For instance, in a pediatric mitochondrial disease trial, integrating remote neuropsychological testing reduced site burden and allowed for wider geographic participation.
Leveraging Mobile Healthcare Services
Mobile clinical services further enhance trial accessibility. These include home nursing visits, mobile phlebotomy, and medication administration, coordinated by third-party vendors.
Advantages include:
- Improved adherence to visit schedules
- Minimized disruption to family routines
- Reduced risk of data variability due to skipped visits
One rare oncology trial achieved 98% visit compliance over 6 months using mobile nursing and home blood draws. This was particularly impactful for immunocompromised patients avoiding clinic visits during flu season.
Remote Data Collection Tools: Wearables and eDiaries
To further support remote visits, sponsors are increasingly deploying wearable devices and eDiaries that collect real-time data on vital signs, sleep patterns, mobility, and symptom occurrence. These tools reduce the need for in-person assessments and enhance the granularity of collected data.
Examples of devices used in rare trials:
- Wrist accelerometers to measure ambulation in neuromuscular disorders
- Pulse oximeters for rare pulmonary conditions
- Tablet-based seizure diaries with photo/video uploads
These technologies must be user-friendly, validated per regulatory standards (e.g., FDA’s Digital Health Precertification Program), and include training support for patients and caregivers.
Ensuring Equity and Regulatory Compliance
Equitable access to rare disease trials is both an ethical and regulatory requirement. Travel and remote support strategies must be offered consistently and fairly to all eligible patients. This includes considerations such as:
- Translation of all materials and support services into local languages
- Additional allowances for patients with disabilities
- Data protection and HIPAA/GDPR compliance for telehealth tools
Trial sponsors must include travel and remote visit plans in their IRB/EC submissions and ensure transparency in the informed consent process regarding available support services.
Reference: Guidelines on Canada’s Clinical Trials Database highlight sponsor responsibilities in providing participant support infrastructure for decentralized models.
Budgeting and Vendor Management
Implementing a comprehensive travel and remote visit strategy requires upfront budgeting and coordination with specialized vendors. Budget planning should include:
- Line items for travel reimbursement and concierge services
- Subscription/licensing fees for telehealth platforms
- Home nursing and sample logistics costs
- Wearable device procurement, training, and data management
Preferred vendors should demonstrate prior experience with rare disease populations and regulatory familiarity across regions. KPIs such as time-to-site activation, patient onboarding rate, and visit completion metrics should be tracked throughout the trial.
Case Study: Combined Reimbursement and Remote Strategy
In a 2022 Phase II trial for congenital hyperinsulinism, the sponsor implemented a combined model:
- Travel reimbursement for site initiation and final visits
- Monthly remote assessments with ePRO and telehealth
- Home delivery of investigational drug with nurse-administered injection
Results:
- Enrollment completed 2 months ahead of schedule
- Patient satisfaction score: 9.5/10 across 3 countries
- No protocol deviations linked to visit scheduling
This hybrid approach significantly improved access for rural and underserved participants without compromising trial integrity.
Conclusion: Making Rare Disease Trials Truly Accessible
Travel reimbursement and remote visit solutions are not auxiliary—they are foundational to modern rare disease trial success. By reducing logistical barriers, sponsors enable broader inclusion, faster recruitment, and higher retention. When designed with transparency, equity, and regulatory alignment in mind, these strategies empower families to participate confidently and comfortably in advancing therapies for rare conditions.